摘要
Chimeric antigen receptor(CAR)T-cell therapy utilizes patients’own T lymphocytes that are engineered to attack cancer cells[1,2,3].With the US Food and Drug Administration(FDA)approval of four CD19-and one BCMA-targeted CAR therapy for B cell malignancies[4,5],CAR T-cell therapy has finally reached the status of a medicinal product.
基金
This work was supported by funds from the National Natural Science Foundation of China(No.31991171,81830002,31870873,81830006,and 81830004)
the Science Technology Department of Zhejiang Province(No.2021C03117)
the China Postdoctoral Science Foundation(No.2021M690184 and 2021M690186).
